First Personalized Gene Therapy Using Base Editing Shows Promising Results in Baby with Rare Disorder
- Researchers treated a Pennsylvania baby with a rare genetic disorder using a personalized gene editing therapy in early 2025.
- The baby, diagnosed with severe CPS1 deficiency shortly after birth, received a custom therapy created within six months to fix his faulty gene.
- The treatment used lipid nanoparticles to deliver CRISPR-based editing to liver cells, and the infant showed improved eating, recovery from colds, and reduced medication.
- Dr. Kiran Musunuru noted the therapy's cost was comparable to an $800,000 liver transplant and expected costs to fall as development speeds and economies of scale improve.
- Experts predicted this milestone could accelerate treatments for rare genetic diseases within five to ten years, potentially helping millions left behind by current genetic medicine.
280 Articles
280 Articles
How a custom-made gene therapy could save one baby's life
A baby born with a rare, life-threatening genetic disease is now thriving after receiving an experimental gene-editing treatment. He's one of the first to be successfully treated with a bespoke therapy targeting a tiny but deadly error in his DNA. His doctors hope the technology could one day help the estimated 350 million people worldwide with rare diseases.


A Baby Receives the World's First Personalized Genetic Treatment
A baby with a rare and incurable disease became the first patient in the world to benefit from personalized genetic therapy, a hopeful achievement for other pathologies, an American medical team announced on Thursday. KJ Muldoon, a plump-faced, blue-eyed, nine-month-old baby, was diagnosed shortly after being born with a very rare and severe metabolic disorder called "carbamil phosphate deficiency synthetase" or CPS1. This disease is caused by m…
Coverage Details
Bias Distribution
- 58% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage